you need patience my friend
No link added
Meta: Nobody Uses AI Better
Meta is using artificial intelligence to make its apps not just addictive, but better at predicting what people want to buy—pushing it from “showing ads” toward taking a cut of shopping itself. That upside comes with big bets on new infrastructure, tougher regulation risks, and the question of whether all that spending really pays off.Read more
Lululemon Got Boring Right About the Time It Got Cheap. That's Usually the Point
Lululemon’s growth story looks stuck just as shoppers and the market start treating the brand as yesterday’s news, even though the business still throws off a lot of cash and has room to grow outside North America. The key question is whether new leadership can refresh the products and protect the brand’s “cool” before rising competition, tariffs, and discounting do lasting damage.Read more
Robinhood Markets will skyrocket with 25% revenue growth
Robinhood could see a surge in trading if new rules make it easier for everyday people to day trade and if calmer headlines lift the mood in markets. But the same forces can swing the other way, and the business also depends heavily on what happens in crypto.Read more
Hermès - Expensive bags, and expensive stock. And the story of €14 billion of bearer shares gone missing.
About Hermès International SA Hermès International SA is a French luxury goods manufacturer. Its core business is leather goods.Read more
Coca-Cola’s Enduring Moat in a Health-Conscious World: Steady Compounder Poised for 5-10% Annual Returns Through Emerging Market Dominance
Business Model in Simple Terms Imagine Coca-Cola as the world’s most powerful “thirst quencher” franchise. The company doesn’t bottle most of its drinks—it sells concentrated syrup and branding rights to independent bottlers worldwide.Read more
The "Physical AI" Monopoly – A New Industrial Revolution
Tesla ($TSLA) has officially exited the automotive peer group. By dismantling legacy Model S/X lines to build humanoid robots, the company has declared its transition from a car manufacturer to the world’s first "Physical AI" platform.Read more
Looking to be second time lucky with a game-changing new product
Unicycive’s kidney drug aims to make life easier for dialysis patients by cutting down the daily pill burden, and it could finally reach the market after a manufacturing setback. The next big moment is the regulator’s decision, but the same manufacturing and rollout risks still hang over the story.Read more
Roche Holding AG To Benefit From Strong Drug Pipeline In 2027 And Beyond
Roche is lining up a new wave of potential hit medicines across obesity, cancer, and multiple sclerosis, with many important trial results expected soon. The big question is whether these programs succeed before tougher competition and upcoming patent expiries start to bite.Read more
Insiders Sell, Investors Watch: What’s Going On at PG?
Over the last year, the share price of Procter & Gamble (PG:NYSE) has fallen from around $175 to roughly $140, with most of the decline occurring since March. This weakness may partly reflect layoffs announced earlier in the year amid tariff-related uncertainty, and the stock may now be drifting into oversold territory.Read more
